SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001136261-22-000351
Filing Date
2022-11-23
Accepted
2022-11-23 16:03:51
Documents
12
Period of Report
2022-11-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 24171
  Complete submission text file 0001136261-22-000351.txt   197609

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE seel-20221121.xsd EX-101.SCH 3033
3 XBRL LABEL FILE seel-20221121_lab.xml EX-101.LAB 34476
4 XBRL PRESENTATION FILE seel-20221121_pre.xml EX-101.PRE 22595
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3596
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

IRS No.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22245 | Film No.: 221416312
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences